This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines across Europe. Rare diseases drugs have always faced challenges when it comes to HTA approvals, even as governments bring in more regulatory policies that make their path through assessment easier. Several factors make it difficult for HTA bodies often to assess orphan drugs, including a lack of robust trial data due to difficulties in finding patients, the absence of randomised controlled tri
Otrivine Extra Dual Relief is a pharmacy only medication and the only over the counter product containing ipratropium bromide for the management of congestion and runny nose caused by colds. This post summarises the essential information about Otrivine Extra Dual Relief nasal spray. 1. Otrivine Extra Dual Relief indicated use Otrivine Extra spray is used for the management of congestion and rhinorrhoea caused by colds. 2.
Recently, the Healthcare Businesswomen’s Association (HBA) held a webinar entitled, Virtual Best Practices: Clarity, Collaboration and Connecting , which dove into the topic of “Zoom fatigue,” a new, commonly used term defined by the draining feeling you experience after a day of long, unnecessary meetings. We are all facing new challenges in the rapidly changing work environment.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pfizer has signed a multi-year agreement with Gilead to manufacture and supply the COVID-19 antiviral remdesivir, which is also being tested in combination with other drugs in an effort to fight the pandemic. Under the terms of the agreement Pfizer will become one of several external partners who manufacture the investigational treatment for the disease.
The bipartisan bill calls for an assessment of the countryâs pharma supply chain, including potential vulnerabilities and impact of foreign manufacturing.
The UK government has asked pharma companies to build a six-week stockpile of drugs and find alternative shipping routes to the congested Dover-Calais crossing as the country heads for Brexit at the end of the year. In a letter , Steve Oldfield, chief commercial officer at the Department of Health and Social Care, said the government is focused on preventing potential disruption to any categories of medical supplies.
A leader from the scientific software provider discusses the most challenging obstacles in the pharma supply chain, and solutions that can conquer them.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pre-Interview Tips for Pharmacy Professionals | Tip #1 with Tom Alig | Vice President of Staffing at Indispensable Health Hi, I am Tom Alig, VP of Staffing with Indispensable Health. I’ve been recruiting pharmacists and pharmacy technicians since 2004, and I’ve seen the things good candidates do to separate themselves, and I’ve seen the mistakes that some candidates make.
Shares in Redx Pharma were soaring this morning after it licensed its preclinical fibrotic disease drug RXC006 to AstraZeneca. The company’s shares were valued as high as 95p on the London Stock Exchange following the announcement, the highest they had been since 2015. AstraZeneca has bought an exclusive global licence to develop and market RXC006, a porcupine inhibitor for fibrotic diseases including idiopathic pulmonary fibrosis (IPF).
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
While not incredibly common, medications can cause dysregulation of our body’s thermoregulation process and cause a rise in core temperature in the presence of normal core body temperature which leads to hyperthermia. Before we get to the drugs that cause hyperthermia, let’s review thermoregulation. Our body is able to regulate our core temperature to keep […].
The UK digital mental health support platform Kooth has joined with five of the UK’s well known Instagram influencers to launch a campaign to help students deal with the pressures of exam results season. The campaign encourages the hundreds of thousands of students waiting to receive their exam results, to stay mentally strong and know they have access to support, if needed.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
As of August 1st, 2020, pharmacogenomics has been added to the BCMTMS exam content outline. We’ve updated our material to include a review of pharmacogenomic principles and common medications that may be affected by genetic variations. In addition, we’ve added pharmacogenomics quiz questions to our quiz bank. I wanted to share a sample of our […].
The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease. Blenrep (belantamab mafodotin) has been approved in patients who have received at least four therapies including an anti-CD38 such as Darzalex, a proteasome inhibitor and an immunomodulatory agent. This is an accelerated approval based on response data and GSK may need survival data from a larger trial to keep the drug on the market in the longer ter
As populations age, multimorbidity becomes an increasingly pertinent issue for healthcare systems. A new action group from the ABPI seeks to bring the NHS, academia and industry together to find new ways to address the problem. The Association’s Dr Sheuli Porkess and Professor Janet Lord from the University of Birmingham tell us more. Multimorbidity is an increasing issue for healthcare and the NHS.
Bringing clinical trials to patients – rather than the reverse – could be the key to improving recruitment into studies and making them faster, cheaper and more likely to succeed, according to one clinical research organisation (CRO). There’s already plenty of support from regulators for virtual or ‘decentralised’ trials, including from former FDA Commissioner Scott Gottlieb who said last year that the agency was encouraging adoption of this approach to make trials more “agile and efficient”, as
The current level of test and trace in the UK is inadequate to prevent a sharp increase in coronavirus infections when schools reopen in September and there is further relaxation of social distancing rules, according to scientists. A second wave of COVID-19 could be avoided if enough people are tested and traced, according to the team from University College London and the London School of Hygiene & Tropical Medicine.
Biogen has bought a licence to co-develop and co-market potential Parkinson’s disease drugs with US biotech Denali, in a deal worth more than $2.1 billion. Denali has been working on small-molecule compounds capable of crossing the blood-brain barrier and Biogen has bought a licence to co-develop and co-market compounds known as LRRK2 inhibitors in Parkinson’s disease.
Health technology firms Cerner and LRVHealth have invested $6 million in Xealth to scale up its business offering digital health tools to patients and clinicians. The companies said the new relationship aims to give patients control over their own digital data so they can be more engaged in their treatment plans. Cerner and LRVHealth join Xealth’s other investors Atrium Health, Cleveland Clinic, Froedtert and the Medical College of Wisconsin, MemorialCare Innovation Fund, Providence Ventures and
The perception of pharma and medical product companies has surged forward since the start of the COVID-19 pandemic, but they still lie mostly outside the top-rated firms in the FutureBrand Index. Roche, AstraZeneca, Novo Nordisk, and Sanofi all shot up the rankings in the first edition of the report since the start of the coronavirus crisis, but the big loser was Gilead Sciences, falling 71 places to 74 in the list since the last edition in 2018.
An executive from Pharmaceutical Associates Inc. believes bringing drug manufacturing back to the country will help avoid shortages and other disasters.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
122 
Let's personalize your content